News
06-07-2010, 07:22 AM
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today preliminary clinical data from its ongoing Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.
More... (http://www.news-medical.net/news/20100607/Alnylam-presents-interim-data-from-ALN-VSP02-Phase-I-trial-for-liver-cancer-at-ASCO-2010.aspx)
More... (http://www.news-medical.net/news/20100607/Alnylam-presents-interim-data-from-ALN-VSP02-Phase-I-trial-for-liver-cancer-at-ASCO-2010.aspx)